Skip to main content
Hemab Therapeutics Holdings, Inc. logo

Hemab Therapeutics Holdings, Inc. — Investor Relations & Filings

Ticker · COAG ISIN · US4234941031 Manufacturing
Filings indexed 19 across all filing types
Latest filing 2026-05-21 Interim / Quarterly Rep…
Country US United States of America
Listing COAG

About Hemab Therapeutics Holdings, Inc.

https://www.hemab.com/

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. The company aims to pioneer the first preventative treatments and functional cures, reimagining the standard of care for blood coagulation disorders. Its pipeline includes HMB-001, currently in Phase 2 for Glanzmann Thrombasthenia, and HMB-002, in preclinical development for von Willebrand disease. Hemab addresses the unmet needs of patients who currently lack adequate prophylactic treatment options, emphasizing prevention over management.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2026
2026-05-21 English
8-K
Regulatory Filings
2026-05-21 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-05-11 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-05-11 English
8-K
Regulatory Filings
2026-05-11 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-05-08 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.